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Genome instability occurs early in the development of most cancers. Bester et al. now provide
evidence that oncogenic signals trigger cell division without coordinate nucleotide synthesis,
engendering aberrant DNA replication and damage that could promote carcinogenesis. A
mismatch between proliferation andmetabolite productionmay characterize oncogenic cell cycles.Cellular proliferation is a normal andneces-
saryaspectofdevelopment andphysiolog-
icalmaintenance. Unchecked proliferation,
however, leads to cancer. Cells have
evolved a series of safeguards, such as
tumor suppressors like p53, to guard
against abnormal proliferation, but how
do cells distinguish between normal and
oncogenic cell cycles? One view is that
DNA damage is part of the equation
becauseoncogenicstimuli innonmalignant
cells trigger DNA breaks (Bartkova et al.,
2005; Gorgoulis et al., 2005) and p53 acti-
vation (Serrano et al., 1997), leading to
arrested growth. But it has remained spec-
ulative how oncogenic cell cycles might
activate the DNA damage response when
normal but equally vigorous proliferation
does not, although aberrant DNA replica-
tion has been implicated circumstantially
(Di Micco et al., 2006; Venkitaraman,
2005). In this issue, Bester et al. (Bester
et al., 2011) report provocative findings
that may help to close the circle between
oncogenic cell cycles and the induction of
replication-associated damage.
Bester et al. begin by inappropriately
activating the Rb-E2F pathway, a network
of proteins that normally monitors entry
into the cell division cycle and is very
frequently altered in cancers. They employ
primary cultures of human keratinocytes
from skin biopsies in which no genetic
alterations permissive for neoplastic trans-
formation are likely to pre-exist. This
deserves emphasis because many prior
studies have relied either on cancer cell
lines or immortalized but nontransformed
cell lines. Although cell lines of these types
may possess intact p53, they will almostindubitably have genetic alterations
affectingother tumorsuppressorpathways
to permit unceasing growth in culture.
These additional alterations may have
made it more difficult in prior work to spot
the differences between normal and onco-
genic cell cycles. Bester et al. activate the
Rb-E2F pathway either by introducing into
the keratinocytes the E6 and E7 oncopro-
teins from human papillomavirus (HPV),
a cause of human cervical cancer, or by
overexpressing cyclin E, an event charac-
teristic of breast and other epithelial
tumors.
The authors analyze the progress of
DNA replication in keratinocytes exposed
to these oncogenic challenges using DNA
fiber combing. Consistent with the prior
results, they find that there is a marked
decrease in the rate and symmetry of
replication fork progression away from
replication origins when the Rb-E2F
pathway has been activated by E6/E7.
Also in accordance with previous results,
Bester et al. show that these anomalies
in replication are followed by increasing
evidence of instability at genomic sites
thought particularly vulnerable to replica-
tion-associated damage (‘‘fragile sites’’),
such as loss of heterozygosity or copy
number variation. So far, these results
provide unsurprising but welcome confir-
mation that oncogenic activation of the
Rb-E2F pathway is sufficient to trigger
aberrant replication and genome insta-
bility in primary cell cultures. The authors
go on to show that the cells exhibit an
enhanced propensity for colony out-
growth in soft agar. These results raise
a number of questions that remain topicsCellfor future study. For example, how do
oncogene-challenged keratinocytes sur-
vive and divide for so long in the face of
continuing DNA damage? Must the cells
overcome checkpoint activation and/or
apoptosis to do this, and if so, how do
these selective pressures influence the
observed genomic instability?
These issuesaside, themostprovocative
and interesting thread in this study, in this
author’s view, begins with the authors’
surprising finding that E6/E7-bearing kera-
tinocytes exhibit a 2- to 5-fold decrease in
their content of all four dNTPs. Supple-
menting the culture media with exoge-
nously supplied nucleosides was sufficient
to reverse the observed decrease in repli-
cation fork progression induced by E6/E7
orcyclinE,suggestingacausalconnection.
This appears to be specific to cells under-
going the oncogenic challenge because
nucleoside supplementation had little
effect on replication dynamics in donor-
matched but unchallenged keratinocytes.
Nucleoside supplementation was enough
not only to restore normal replication
parameters in the E6/E7- or cyclin E-ex-
pressing cells, but also to prevent DNA
breakage marked by phosphorylation of
histone H2AX and to suppress the out-
growth of colonies in soft agar.
Bester et al. then attempt to uncover
why nucleotide deficiency is apparently
associated with oncogenic cell cycles. In
this regard, their results are suggestive,
but not yet definitive. The authors find
that cells in which the Rb-E2F pathway
hasbeenactivatedbyE6/E7orcyclinEup-
regulate the transcription of genes that
participate in the cell division cycle and145, April 29, 2011 ª2011 Elsevier Inc. 337
Figure 1. A Mismatch between Proliferation and Metabolite
Production May Characterize Oncogenic Cell Cycles
During normal proliferation elicited, for example, by growth factor stimulation
(top), cellular programs leading to DNA replication are coordinated with
nucleotide biosynthesis and other metabolic programs that are necessary to
sustain growth through the action of c-Myc or other factors. In contrast,
oncogenic stimuli (lightning bolt, bottom) may work downstream to activate
cell division, bypassing the metabolic programs that are associated with
normal growth. This forces DNA replication to proceed under suboptimal
conditions such as nucleotide deficiency, engendering aberrations that cause
DNA damage leading to genome instability. Similarly, other metabolic defi-
ciencies associated with oncogene-driven proliferation could evoke different
cellular stress reactions detected by tumor suppressors like p53 or ARF, which
might promote carcinogenesis if left undetected.DNA replication but, signifi-
cantly, failed to alter the
synthesis ofmost of the genes
required for rate-limiting steps
in nucleotide synthesis. The
authors thus speculate that
the uncoordinated regulation
of genes involved in prolifera-
tion without the concomitant
elevation of nucleotide syn-
thesis genes forces cells to
replicate their DNAunder sub-
optimal conditions, leading to
replication anomalies and,
eventually, DNA damage.
The authors find that en-
forced expression of c-Myc
(Liu et al., 2008; Mannava
et al., 2008) can prevent the
replication anomalies induced
by oncogenic challenge and
even inhibit colony formation
in soft agar. Notably, the ap-
parently anti-oncogenic effect
of c-Myc expression in this
setting contrasts with its
frequent overexpression in
later-stage tumors, which is
apparently required for their
continued outgrowth (Soucek
et al., 2008). The significance
of the anti-oncogenic role of
c-Myc expressed heterolo-
gously in this way remains
unclear. Not only does the
experiment leave open the
possibility that effects of
c-Myc other than on nucleo-
tide biosynthesis are respon-
sible, but it also suggests thatc-Myc isnot induced,at least initially,during
oncogene-driven growth, as it normally is
duringprogrammedcell proliferation,which
is puzzling.
Indeed, this last point suggests a tanta-
lizing hypothesis that cellular proliferation
in response to normal stimuli like growth
factors may induce a coordinate and
appropriate transcriptionalprogram,driven
by c-Myc or other factors, sufficient to
sustain DNA replication (Figure 1, top). In
contrast, oncogenic stimuli may work
downstreamofc-Mycand theother factors
induced during normal proliferation,
leading to an insufficiency of genes like
those necessary for nucleotide biosyn-338 Cell 145, April 29, 2011 ª2011 Elsevier Inthesis (Figure 1, bottom). Not only could
this mismatch force cells to carry out DNA
replication under suboptimal circum-
stances, as shown by Bester et al., but it
could also provoke further ‘‘stress’’ reac-
tions when cells attempt to execute other
metabolic activities usually associated
with proliferation but without the benefit of
the function of c-Myc or other factors, elic-
iting a variety of cellular anomalies during
oncogene-driven proliferation. Cells prob-
ably use several different tumor-suppres-
sive pathways to detect these anomalies.
This may help to explain why different
tumor suppressors like ARF as well as
p53, for instance, appear to play nono-c.verlapping roles in arresting
oncogene-induced prolifera-
tion (Lowe et al., 2004). The
nucleotide deficiency and
ensuing DNA damage de-
tected by Bester et al. might,
therefore, represent only the
proverbial tip of the iceberg.
Nonetheless, their work serves
to open a new window into the
currently impenetrablemystery
of how cells can distinguish
normal from oncogene-driven
cell cycles, a problem that is
central to our understanding
of the earliest steps in
carcinogenesis.REFERENCES
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